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(57) ABSTRACT 
Amethod is provided for gene suppression in eukaryotes by 
transformation with a recombinant construct containing a 
promoter, at least one antisense andlor sense nucleotide 
sequence for the gene(s) to be suppressed, wherein the 
nucleus-to-cytoplasm transport of the transcription products 
of the construct is inhibited. In one embodiment, nucleus- 
to-cytoplasm transport is inhibited by the absence of a 
normal 3' UTR. The construct can optionally include at least 
one self-cleaving ribozyme. The construct can also option- 
ally include sense andlor antisense sequences to multiple 
genes that are to be simultaneously down-regulated using a 
single promoter. Also disclosed are vectors, plants, animals, 









DOWN-REGULATION OF SINGLE GENES AND 
SIMULTANEOUS DOWN-REGULATION OF 
MULTIPLE GENES BY NUCLEAR 
LOCALIZATION OF RNA TRANSCRIPTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
[0001] This application claims the benefit of U.S. Provi- 
sional patent application Ser. No. 601222,510, filed Aug. 2, 
2000, which is herein incorporated by reference in its 
entirety for all purposes. 
BACKGROUND 
[0002] The present invention is directed to a method for 
suppressing the expression of a gene or genes using nuclear 
localized RNA transcripts. Also, this invention is directed to 
the use of a single promoter to down-regulate more than one 
gene simultaneously. 
[0003] There are currently at least four known methods for 
gene down-regulation or suppression in plants. One strategy 
is targeted gene disruption(s) or gene knockout(s) that relies 
on homologous recombination. "Knockout" refers to a DNA 
sequence that has been altered via any known means, for 
example, deletion, insertion, point mutation or rearrange- 
ment, so as to eliminate the function of the gene product. 
One strategy that generates a gene knockout in plants 
employs chimeric RNNDNA oligonucleotides to generate 
site-specific mutations including gene knockouts (Beetham 
et al., (1999) Proc. Natl. Acad. Sci. USA, 963774). This 
technology requires specialized oligonucleotides and biolis- 
tic delivery that produces large numbers of undesirable 
off-type transgenics. It is also not clear whether the oligo- 
nucleotide-directed mutations are restricted to target genes. 
[0004] Another strategy for gene down-regulation is 
expression of antisense transcripts, where the gene of inter- 
est has an antisense orientation between a promoter and an 
appropriate 3' terminal sequence for nuclear export. As is 
well known, a cell manufactures protein by transcribing the 
DNA of the gene for that protein to produce RNA, which is 
then processed (e.g. by the removal of introns) into mes- 
senger RNA (mRNA) and finally translated by ribosomes 
into protein. This process may be inhibited by the presence 
in the cell of "antisense RNA". Therefore, as used herein, the 
term "antisense RNA" means an RNA seauence which is 
complementary to a sequence of bases in a RNA: comple- 
mentary in the sense that each base (or a majority of bases) 
in the antisense sequence (read in the 3' to 5' sense) is 
capable of pairing with the corresponding base (G with C, A 
with U) in the mRNA sequence read in the 5' to 3' sense. It 
is believed that this inhibition takes place by formation of a 
complex between the two complementary strands of RNA, 
preventing the production of protein. How this works is 
uncertain: the complex may interfere with further transcrip- 
tion, processing, transport or translation, or lead to degra- 
dation of the mRNA, or have more than one of these effects. 
Such antisense RNA may be produced in the cell by trans- 
formation with an appropriate DNA construct arranged to 
transcribe part of the antisense or anticoding strand (as 
opposed to the template strand) of the relevant gene (or of 
a DNA sequence showing substantial homology therewith). 
[0005] The use of this technology to down-regulate the 
expression of specific plant genes has been described, for 
example in European Patent Publication No 271988. Reduc- 
tion of gene expression by the use of antisense RNA has led 
to a change in the phenotype of the plant: either at the level 
of gross visible phenotypic difference e.g. lack of lycopene 
synthesis in the fruit of tomato leading to the production of 
yellow rather than red fruit, or at a more subtle biochemical 
level e.g. change in the amount of polygalacturonase and 
reduction in depolymerisation of pectins during tomato fruit 
ripening (U.S. Pat. Nos. 5,073,676, 5,107,065, 5,569,831; 
Smith et al, (1988) Nature, 334,724-726; Smith et al, (1990) 
Plant Mol. Biol. 14, 369-380). Thus, antisense RNA is one 
method used in achieving down-regulation of gene expres- 
sion in vlants. However. antisense down-remlation is often 
u 
leaky since there is frequently a reduction of the gene 
product but not always a complete shut-down of the gene 
product. 
[0006] In some instances, antisense constructs have been 
combined with ribozymes. Ribozymes are catalytic RNA 
molecules that can promote specific biochemical reactions 
without the need for auxiliary proteins. U.S. Pat. No. 5,814, 
500 discloses a construct containing an antisense sequence 
flanked on both ends by a U1 snRNA stem loop structure. 
The stem loop structure is believed to give the antisense 
construct enhanced stability by being resistant to nuclease 
activity and by being enriched in the nucleus. In one 
embodiment, the construct contains a ribozyme sequence 
which cleaves a target RNA and is located between stem 
loop structures which were placed on each end of the 
construct. The patent teaches the use of this construct in 
animal cells. Likewise. U.S. Pat. No. 5.908.779 discloses 
, , 
mammalian cells containing a promoter, an antisense 
sequence and a cis-ribozyme. The use of antisense construct 
harboring cis-acting ribozymes has not been successfully 
applied to plants. 
[0007] A third strategy for gene down-regulation is co- 
suppression. Co-suppression can occur when the gene of 
interest is expressed in the sense orientation between a 
promoter and an appropriate 3' terminal sequence for nuclear 
export. Co-suppression results in reduced expression of the 
transgene as well as the endogenous gene. Insertion of a 
related gene or promoter into a plant can induce rapid 
turnover of homologous endogenous transcripts, a process 
believed to have many similarities to the mechanism respon- 
sible for antisense RNA inhibition. The effect depends on 
sequence identity between the transgene and the endogenous 
gene. Some cases of co-suppression resemble RNA inter- 
ference (the experimental silencing of genes by the intro- 
duction of double-stranded RNA), as RNAseems to be both 
an important initiator and a target in these processes. Various 
regulatory sequences of DNA can be altered (promoters, 
polyadenylation signals, post-transcriptional processing 
sites) or used to alter the expression levels (enhancers and 
silencers) of a specific mRNA. 
[0008] The fourth strategy for gene down-regulation or 
suppression is RNA interference. Introduction of double- 
stranded RNA induces potent and specific gene silencing, a 
vhenomenon called RNA interference or RNAi. In RNAi. 
inverted repeats, which presumably form strong secondary 
structure in vivo, cause genetic down-regulation. (Sharp et 
al. (2000) Science 287:2431-2433). The mechanism of how 
RNAi results in the loss of the targeted homologous mRNA 
is still not well understood. The RNAi stratenv is effective 
u, 
for gene down-regulation in plants, and is distinct from the 
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method using expression of antisense transcripts because the 
base pairing in RNAi occurs intramolecularly. 
[0009] Importantly, current models generally indicate that 
the mechanisms for the above down-regulation strategies 
originate in the cytoplasm of the cell. (Marx, J. (2000) 
Science 288:1370-1372; Wolfe et al., (1999) Science 
286:481-486; Waterhouse et al. (1998) PNAS 95:13959- 
13964). Cytoplasmic localization of transcripts presumably 
causes dilution of the transcripts as opposed to nuclear 
localization. Thus. there remains a need in the art for 
methods useful in the suppression and down-regulation of 
genes which uses a nuclear localization strategy of RNA 
transcripts in order to increase the efficacy of gene down- 
regulation. 
SUMMARY 
[0010] One aspect of the present invention, therefore, 
provides a method by which expression of genes can be 
suppressed (down regulated). Described herein are con- 
structs and methods which allow the nuclear localization of 
RNA. The presence of high concentrations of either sense or 
antisense RNA within the nucleus results in the suppression 
of the gene or genes of interest. 
[0011] Another aspect provides a method for suppressing 
gene expression in a eukaryotic cell comprising transform- 
ing the cell with a recombinant construct comprising, a 
promoter functional in the cell operatively linked to a sense 
nucleotide sequence of a gene to be suppressed, wherein 
nucleus-to-cytoplasm transport of transcription products of 
the construct is inhibited. In one embodiment, the construct 
can contain sequences for the suppression of multiple genes. 
[0012] Afurther aspect provides a method for suppressing 
gene expression in a eukaryotic cell comprising transform- 
ing the cell with a recombinant construct comprising, a 
promoter functional in the cell operatively linked to a 
plurality of antisense nucleotide sequences of a gene or 
genes to be suppressed, wherein nucleus-to-cytoplasm trans- 
port of transcription products of the construct is inhibited. 
[0013] Still another aspect provides a method for sup- 
pressing expression of a gene in a plant cell comprising, 
transforming the plant cell with a recombinant construct 
comprising, a promoter functional in said plant; and an 
antisense nucleotide sequence for the gene to be suppressed, 
wherein nucleus-to-cytoplasm transport of transcription 
products of the construct is inhibited. 
[0014] Yet another aspect provides a recombinant vector 
comprising a promoter functional in a eukaryotic cell opera- 
tively linked to at least one sense nucleotide sequence of at 
least one gene to be suppressed, wherein nucleus-to-cyto- 
plasm transport of transcription products of said at least one 
nucleotide sequence is inhibited. 
[0015] An additional aspect provides a recombinant vector 
comprising a promoter functional in a eukaryotic cell opera- 
tively linked to a plurality of antisense nucleotide sequences 
of at least one gene to be suppressed, wherein nucleus-to- 
cytoplasm transport of transcription products of said at least 
one nucleotide sequence is inhibited. 
[0016] Another aspect provides a recombinant vector 
comprising a promoter functional in a plant; and at least one 
antisense sequence for at least one gene to be suppressed; 
wherein nucleus-to-cytoplasm transport of transcription 
products of said at least one nucleotide sequence is inhibited. 
[0017] Still another aspect provides, a eukaryotic cell 
whose genome includes a recombinant construct comprising 
a promoter functional in the eukaryotic cell operatively 
linked to at least one sense nucleotide sequence of at least 
one gene to be suppressed, wherein nucleus-to-cytoplasm 
transport of transcription products of the construct is inhib- 
ited. 
[0018] An additional aspect provides, a eukaryotic cell 
whose genome includes a recombinant construct comprising 
a promoter functional in the eukaryotic cell operatively 
linked to a plurality of antisense nucleotide sequences of at 
least one gene to be suppressed, wherein nucleus-to-cyto- 
plasm transport of transcription products of the construct is 
inhibited. 
[0019] A further aspect provides, a plant cell whose 
genome includes a recombinant construct comprising, a 
promoter functional in said plant cell operatively linked to at 
least one antisense sequence for at least one gene to be 
suppressed; wherein nucleus-to-cytoplasm transport of tran- 
scription products of the construct is inhibited. 
[0020] In still further aspects, any of the aforementioned 
constructs which contain more than one sequence can com- 
prising a combination of sense and antisense sequences. 
[0021] Additional aspects include, plants and animals 
comprising any of the aforementioned cells or constructs; 
and seed, gametes, embryos, progeny and uniform popula- 
tions obtained from such plants or animals. 
[0022] In any of the aforementioned aspects, the inhibition 
of nucleus-to-cytoplasm transport can be due to the absence 
of appropriate 3' terminal sequences (3' UTR), which are 
typically necessary for nucleus-to-cytoplasm transport of 
transcription products, or the presence of 3' terminal 
sequences that prevent or avoid nuclear-to-cytoplasm trans- 
port of transcription products. 
[0023] In additional aspects, any of the aforementioned 
constructs can include at least one self cleaving ribozyme. 
[0024] In still further aspects, any of the aforementioned 
promoters can be constitutive, inducible, tissue specific, 
developmentally regulated, or a suitable combination such 
as an inducible, tissue specific promoter. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0025] These and other features, aspects, and advantages 
of the present invention will become better understood with 
regard to the following description, appended claims and 
accompanying figures where: 
[0026] FIG. 1 shows the arrangement of pertinent DNA 
sequences for the binary vectors pPTN102, pPTN110, 
pPTN111, pPTN112 and pPTN113. The sizes of the different 
regions are not to scale. Abbreviations used are as follows: 
LB=left border, hpt=hygromycin phosphotransferase ORF, 
Pnos=nopaline synthase promoter, E35S=cauliflower 
mosaic virus 35s enhancer, TEV=tobacco etch virus trans- 
lational leader, T35S=cauliflower mosaic virus 35s  3' ter- 
minal sequence, RB=right border, nptII=neomycin phospho- 
tranferase ORF, P35S=cauliflower mosaic virus promoter, 
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RZ=ribozyme, GUS sense=GUS ORF in sense orientation, 
anti GUS=GUS ORF in antisense orientation. 
[0027] FIG. 2 shows the arrangement of pertinent DNA 
sequences for the binary vectors pPTN166, pPTN167, 
pPTN170 and pPTN326 that a single gene knockout con- 
structs for soybean. The sizes of different regions are not to 
scale. Abbreviations are the same as for FIG. 1 with the 
following additions: bar=glufosinate resistance gene, FAD2- 
1=FAD2-1 gene in sense orientation, anti-FAD2-l=FAD2-1 
gene in antisense orientation, PhP=Phaseolin promoter. 
[0028] FIG. 3 shows the arrangement of pertinent DNA 
sequences for the binary vectors pPTN300 and pPTN303 
that are dual gene knockout constructs for soybean. The 
sizes of different regions are not to scale. Abbreviations are 
the same as for FIGS. 1 and 2 with the following additions: 
B-C-=fl-conglycinin promoter, FatB=FatB gene in sense 
orientation. 
[0029] FIG. 4 shows a photograph of nuclei-enriched 
fraction from tobacco. The color picture on the left was 
stained with propidium iodide. The phase contrast picture on 
the right is of the same region. 
[0030] FIG. 5 shows a Northern hybridization for trans- 
genic tobacco harboring pPTN102 (total RNA, lane 1 and 
nuclei RNA, lane 2), pPTNllO (total RNA, lane 3 and nuclei 
RNA, lane 4), pPTNll l  (total RNA, lane 5 and nuclei RNA, 
lane 6), pPTN112 (total RNA, lane 7 and nuclei RNA, lane 
8), and pPTN113 (total RNA, lane 9 and nuclei RNA, lane 
10). The upper portion was probed with the TEV-GUS 
sequence from pPTN102 and the lower portion was probed 
with rDNA. 
[0031] FIG. 6 shows photographs of in situ hybridiza- 
tions. The pictures in the column on the left were taken using 
the red channel to show nuclei. The pictures in the center 
column were taken using the green channel to show probe 
hybridizations. The pictures in the column on the right are 
the red and green channels combined. The rows of pictures 
are arranged to show tobacco sections harboring pPTNll l  
or pPTN112 probed with either the GUS sense probe or the 
GUS antisense probe. 
DETAILED DESCRIPTION 
[0032] The following detailed description is provided to 
aid those skilled in the art in practicing the present invention. 
Even so, this detailed description should not be construed to 
unduly limit the present invention as modifications and 
variations in the embodiments discussed herein can be made 
by those of ordinary skill in the art without departing from 
the spirit or scope of the present inventive discovery. 
[0033] All publications, patents, patent applications and 
other references cited in this application are herein incor- 
porated by reference in their entirety as if each individual 
publication, patent, patent application or other reference 
were specifically and individually indicated to be incorpo- 
rated by reference. 
[0034] The following abbreviations and definitions are 
used herein. 
[0036] ORF=open reading frame 
[0037] TEV=tobacco etch virus 
[0038] 35S=CaMV35S=cauliflower mosaic virus 35s  
[0039] FAD2-1=An omega-6-desaturase that catalyzes 
desaturation at the omega 6 carbon (sixth carbon from 
the end). 
[0040] ddH,O=deionized, distilled water 
[0041] MOPS=2-(N-Morpho1ino)-2-hydroxypropane- 
sulfonic acid 
[0042] EDTA=ethylenediaminetetraacetic acid 
[0043] SDS=sodium dodecyl sulfate 
[0044] SSC=standard saline citrate (20x SSC=3 M 
NaC1, 0.3 M citrate.2H20, pH=7) 
[0045] TE=10 mM Tris, 1 mM EDTA 
[0047] l x  TBS=20 mM Tris, 0.5M NaC1, pH=7.5 
[0048] TTBS=0.05% Tween 20, l x  TBS 
[0049] BSA=bovine serum albumin 
[0050] FITC=fluorescein isothiocyanate 
[0051] LB=Luria-Bertani medium=lO g bacto-tryptone, 
5 g bacto-yeast extract, 10 g NaCl in one liter water, 
pH=7. 
[0052] T-DNA=that part of the Agrobacterium Ti plas- 
mid that is incorporated into the genome of infected 
plant cells. 
[0053] 3' UTR=3' untranslated region or sequence of a 
gene or the transcription product of that gene. 
[0054] The term "expression" in the context of a gene or 
polynucleotide involves the transcription of the gene or 
polynucleotide into RNA. The term can also, but not nec- 
essarily, involve the subsequent translation of the RNA into 
polypeptide chains and their assembly into proteins. 
[0055] As used herein, "expression vector" means a vector 
that promotes transcription of a gene or polynucleotide. 
When placed in a suitable host cell, transcripts from an 
expression vector can result in synthesis of a protein or 
polypeptide. 
[0056] As used herein, "polynucleotide" and "oligonucle- 
otide" are used interchangeably and mean a polymer of at 
least 2 nucleotides joined together by phosphodiester bonds 
and may consist of either ribonucleotides or deoxyribonucle- 
otides. 
[0057] As used herein, "sequence" means the linear order 
in which monomers occur in a polymer, for example, the 
order of amino acids in a polypeptide or the order of 
nucleotides in a polynucleotide. 
[0058] As used herein, "peptide" and "protein" are used 
interchangeably and mean a compound that consists of two 
or more amino acids that are linked by means of peptide 
bonds. 
[0059] As used herein, "organelle" means any discrete 
structure in a cell that is adapted andlor specialized for the 
performance of one or more vital functions and can include 
plastids and mitochondria. 
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[0060] As used herein, "recombinant construct" is defined 
either by its method of production or its structure. In 
reference to its method of production, e.g., a product made 
by a process, the process is use of recombinant nucleic acid 
techniques, e.g., involving human intervention in the nucle- 
otide sequence, typically selection or production. Alterna- 
tively, it can be a sequence comprising fusion of two nucleic 
acid sequences which are not naturally contiguous to each 
other, but is meant to exclude products of nature, e.g., 
naturally occurring mutants. 
[0061] The present invention is directed to the suppression 
of gene expression by use of a DNA construct comprising a 
promoter, and a sense or antisense sequence for the gene or 
genes to be suppressed wherein the normal nucleus-to- 
cytoplasm transport of the RNA transcript of the construct is 
inhibited. In one embodiment. transvort is inhibited due to 
the absence of the normal 3' terminal sequence. As used 
herein, a "normal" 3' terminal sequence (3' UTR) is a 
sequence found at the 3' end of a gene that is involved in 
nuclear-to-cytoplasm transport of transcription products of 
the gene. The absence of a "normal" 3' UTR from a gene or 
the transcription product of that gene, or the replacement of 
a "normal" 3' UTR with an appropriate alternative sequence 
will prevent or inhibit nucleus to cytoplasm transport of the 
transcription product (Eckner et al., EMBO J., 10:3513- 
3522; Huang and Carmichael (1996) Molec. Cell. Biol., 
16:1534-1542). In another embodiment, the construct also 
includes a self-cleaving ribozyme. It should be recognized 
that the suppression of gene expression need not be com- 
plete. Rather, the rate of translation of the protein encoded 
by the gene to be suppressed need only be decreased when 
compared to the rate of expression observed in the absence 
of the construct. In one embodiment, the rate of expression 
is decreased by at least 10%. In another embodiment, the 
rate of expression is decreased by at least 50% and in yet 
another embodiment, the rate of expression is decreased at 
least 75%. In still another embodiment, the rate of expres- 
sion is decreased at least 95%. 
[0062] The present invention is useful for altering physi- 
ological processes within a cell or tissue. For example, and 
without limitation, the present invention can be used to alter 
the patterns of enzymes produced which in turn can alter 
biochemical pathways resulting in the altered accumulation 
of the end products of such pathways. One non-limiting 
example is the type of fatty acids produced by the plant. 
Examples of other physiological processes which may be 
altered using the present invention include, flowering, and 
the ripening, spoilage of fruit and the fatty acid composition 
of meat and milk. 
[0063] The present invention also has therapeutic uses 
such as the suppression of undesirable genes. These genes 
may be native genes or can be exogenous genes such as 
those due to viral or retroviral infection. Therefore. the 
present invention can be used to resist or treat such infec- 
tions. 
[0064] Any promoter that functions in the chosen host 
may be used in practicing the present invention. The pro- 
moter may be homologous or heterologous to the sequence 
controlled. Promoters useful in the present invention include 
those that confer appropriate cellular and temporal specific- 
ity of expression. Such promoters include those that are 
constitutive or inducible, environmentally-regulated, devel- 
opmentally-regulated, cell-specific, or tissue-specific. In 
plants, often-used constitutive promoters include the CaMV 
35s promoter (Ode11 et al. (1985) Nature 313: 810), the 
enhanced CaMV 35s  promoter, the Figwort Mosaic Virus 
(FMV) promoter (Richins et al. (1987) NAR 20: 8451), the 
mannopine synthase (mas) promoter, the nopaline synthase 
(nos) promoter, and the octopine synthase (ocs) promoter. 
[0065] Useful inducible promoters in plants include heat- 
shock promoters (Ou-Lee et al. (1986) Pvoc. Natl. Acad. Sci. 
USA 83: 6815; Ainley et al. (1990) PlantMol. Biol. 14: 949), 
a nitrate-inducible promoter derived from the spinach nitrite 
reductase gene (Back et al. (1991) Plant Mol. Biol. 17:9), 
hormone-inducible promoters (Yamaguchi-Shinozaki et al. 
(1990) Plant Mol. Biol. 15: 905; Kares et al. (1990) Plant 
Mol. Biol. 15: 905), and light-inducible promoters associ- 
ated with the small subunit of RuBP carboxylase and LHCP 
gene families (Kuhlemeier et al. (1989) Plant Cell 1: 471; 
Feinbaum et al. (1991) Mol. Gen. Genet. 226: 449; Weis- 
shaar et al. (1991) EMBO J. 10: 1777; Lam and Chua (1990) 
Science 248: 471; Castresana et al. (1988) EMBO J. 7: 1929; 
Schulze-Lefert et al. (1989) EMBO J. 8: 651). 
[0066] Examples of useful tissue-specific, developmen- 
tally-regulated promoters in plants include fruit-specific 
promoters such as the E4 promoter (Cordes et al. (1989) 
Plant Cell 1:1025), the E8 promoter (Deikman et al. (1988) 
EMBO J. 7: 3315), the kiwi fruit actinidin promoter (Lin et 
al. (1993) PNAS 90: 5939), the 2 A l l  promoter (Houck et al., 
U.S. Pat. No. 4,943,674), and the tomato pZ130 promoter 
(U.S. Pat. Nos. 5,175,095 and 5,530,185); the 0-conglycinin 
7 s  promoter (Doyle et al. (1986) J. Biol. Chem. 261: 9228; 
Slighton and Beachy (1987) Planta 172: 356), and seed- 
specific promoters (Knutzon et al. (1992) Pvoc. Natl. Acad. 
Sci. USA 89: 2624; Bustos et al. (1991) EMBO J. 10: 1469; 
Lam and Chua (1991) J. Biol. Chem. 266: 17131; Stayton et 
al. (1991) Aust. J. Plant. Physiol. 18: 507). Fruit-specific 
gene regulation is discussed in U.S. Pat. No. 5,753,475. 
Other useful seed-specific promoters include, but are not 
limited to, the napin, phaseolin, zein, soybean trypsin inhibi- 
tor, 7S, ADR12, ACP, stearoyl-ACP desaturase, oleosin, 
Lasquerella hydroxylase, and barley aldose reductase pro- 
moters (Bartels (1995) Plant J. 7: 809-822), the EA9 pro- 
moter (U.S. Pat. No. 5,420,034), and the Bce4 promoter 
(U.S. Pat. No. 5,530,194). Useful embryo-specific promot- 
ers include the corn globulin 1 and oleosin promoters. 
Useful endosperm-specific promoters include the rice glu- 
telin-1 promoter, the promoters for the low-pI a-amylase 
gene (Amy32b) (Rogers et al. (1984) J. Biol. Chem. 259: 
12234), the high-pI a-amylase gene (Amy 64) (Khurseed et 
al. (1988) J. Biol. Chem. 263: 18953), and the promoter for 
a barley thiol protease gene ("Aleurain") (Whittier et al. 
(1987) Nucleic Acids Res. 15: 2515). 
[0067] Other promoters known to control the expression 
of genes in prokaryotic or eukaryotic cells can be used and 
are known to those skilled in the art. For example, the casein 
promoter can be used to direct expression of foreign pro- 
tein(~) in the milk. Promoter hybrids can also be constructed 
to enhance transcriptional activity (Hoffman, U.S. Pat. No. 
5,106,739), or to combine desired transcriptional activity 
and tissue specificity. 
[0068] One embodiment of the present invention involves 
the use of antisense sequences. Antisense sequences can be 
produced by reversing the orientation of the transcribed 
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region of a gene or polynucleotide sequence whose suppres- 
sion is desired. When operatively coupled to a suitable 
transcriptional promoter such as those discussed above, a 
transcript of the antisense DNA strand is produced. The 
production and use of antisense DNA is well known in the 
art and can be found, for example, in Green et al., (1986) 
Annu. Rev. Biochem. 55:569. The transcript of the antisense 
DNA is antisense RNA. Without being bound by theory, it 
is believed that an individual antisense RNA molecule may 
hybridize with a complementary "sense" mRNAmolecule to 
form an RNA-RNA duplex. Such a duplex may prevent the 
sense mRNA molecule from being translated, effectively 
suppressing production of the ultimate gene product, a 
protein. The presence of RNA-RNA duplexes may also 
initiate a sequence-specific RNA degradation pathway with 
the antisense molecules andlor the RNA-RNA duplexes 
playing a role in initiating the degradation pathway, and both 
sense and antisense molecules serving as specific targets for 
degradation. Formation of RNA-RNA duplexes is believed 
to be most efficient when the sense and antisense RNAs are 
retained in close proximity to each other. One advantage of 
the present invention is that the antisense RNA is not 
transported out of the nucleus into the cytoplasm. This 
maintains a relatively high concentration of antisense RNA 
within the nucleus and thereby may increase the likelihood 
that RNA-RNA duplexes will form before the sense mRNA 
is transported to the cytoplasm where translation can occur. 
It will be apparent to one of ordinary skill in the art, that the 
antisense transcript need not encompass the entire gene or 
polynucleotide sequence, but may be a fragment which 
hybridizes to only a portion of the sense RNA. The antisense 
transcript should be of sufficient length to allow specificity 
in binding to the target (sense) transcript. In general, the 
antisense transcript should be at least 10 bases long, 
although the presence of rare sequences may allow the use 
of shorter antisense transcripts. 
[0069] As with antisense sequences, sense sequences used 
in the practice of the present invention need not encompass 
the entire gene. Rather, the sense sequences used can include 
only a portion of the gene. In one embodiment, the sense 
sequences include the coding portion of the gene. In another 
embodiment, the sequences are at least about 10 bases long. 
[0070] An additional embodiment involves the use of a 
self-cleaving ribozyme, preferably located downstream to 
the sense or antisense sequence of the construct. Ribozymes 
are catalytic RNA molecules that can promote specific 
biochemical reactions without the need for auxiliary pro- 
teins. Reactions catalyzed by ribozymes can be either 
intramolecular or intermolecular. Examples of intramolecu- 
lar reactions are self-splicing or self-cleaving reactions 
while intermolecular reactions involve other RNA mol- 
ecules as substrates and more closely approximate true 
enzymatic reactions where the enzyme is unchanged after 
each reaction. In the present invention, a self-cleaving 
ribozyme is used. In one embodiment, the self-cleaving 
ribozyme is the RZ ribozyme described in U.S. Pat. No. 
5,908,779 and Liu and Carmichael (1994) Molec. Biotech- 
nol. 2:107. In one embodiment, the ribozyme replaces the 3' 
terminal sequence normally found in RNA to be transported 
to the cytoplasm for translation. In addition, the ribozyme 
acts to cleave itself from the transcript produced creating a 
free transcript and further insuring that the transcript 
remains within the nucleus. 
[0071] In addition, the present invention can also employ 
constructs that result in RNA with secondary structure 
(RNAi). An example of such secondary structure that 
induces RNAi would be encompassed in a construct that 
expresses a single transcript that has both sense and comple- 
mentary antisense sequences from the target gene or genes. 
[0072] optionally, the construct may also include an 
enhancer. Enhancers are DNA sequences found in eukary- 
otes that increase the rate of transcription of genes present on 
the same molecule, but which do not have promoter activity. 
An enhancer can be placed upstream or downstream of a 
promoter or in forward or reverse orientation without loss of 
activity. 
[0073] The constructs of the present invention are pro- 
duced using methods well known to those of ordinary skill 
in the art which can be found, for example, in standard texts 
such as Sambrook et al., Molecular Cloning, 2nd ed., Cold 
Spring Harbor Laboratory Press, 1989 and Ausubel, et al., 
Short Protocols in Molecular Biology, 3rd ed., Wiley & 
Sons, 1995. In general, recombinant constructs are produced 
by a series of restriction enzyme digestions and ligation 
reactions which result in the desired sequences being incor- 
porated into a plasmid. If suitable restriction sites are not 
available, then synthetic oligonucleotide adapters or linkers 
can be used as is known to those skilled in the art and 
described in the references cited above. The DNAconstructs 
are assembled such that the promoter, sense DNA andlor 
antisense DNA and ribozyme are operatively linked. A 
nucleic acid sequence is operably linked when it is placed 
into a functional relationship with another nucleic acid 
sequence. For example, a promoter is operably linked to a 
sequence if it affects the transcription of the sequence; or a 
ribosome binding site is operably linked to a coding 
sequence if it is positioned so as to facilitate translation. 
[0074] It will be apparent to those of ordinary skill in the 
art, that the precise restriction enzymes, linkers andlor 
adaptors required as well as the precise reaction conditions 
will vary with the sequences and cloning vectors used. The 
assembly of DNA constructs, however, is routine in the art 
and can be readily accomplished by the skilled technician 
without undue experimentation. Non-limiting illustrations 
of the assembly of DNA constructs useful in the present 
invention can be found in the examples that follow. 
[0075] The DNA construct can then be placed into a 
suitable vector to transform a host cell. The vector can be 
either a cloning vector or an expression vector. A cloning 
vector is a self-replicating DNA molecule that serves to 
transfer a DNA segment into a host cell. The three most 
common types of cloning vectors are bacterial plasmids, 
phages, and other viruses. An expression vector is a cloning 
vector designed so that a coding sequence inserted at a 
particular site will be transcribed into mRNA. Both cloning 
and expression vectors contain nucleotide sequences that 
allow the vectors to replicate in one or more suitable host 
cells. In cloning vectors, this sequence is generally one that 
enables the vector to replicate independently of the host cell 
chromosomes, and also includes either origins of replication 
or autonomously replicating sequences. Various bacterial 
and viral origins of replication are well known to those 
skilled in the art and include, but are not limited to, the 
pBR322 plasmid origin, the 2p plasmid origin, and the 
SV40, polyoma, adenovirus, VSV and BPV viral origins. 
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Ausubel et al., ed., Short Pvotocols in Moleculav Biology, 
3rd ed., Wiley & Sons, 1995. 
[0076] Vectors can and usually do contain a selection gene 
or selection marker. Typically, this gene encodes a protein 
necessary for the survival or growth of the host cell trans- 
formed with the vector. Examples of suitable selection 
markers include dihydrofolate reductase (DHFR) or neomy- 
cin resistance for eukaryotic cells and tetracycline or ampi- 
cillin resistance for E. coli. Selection genes in plants include 
genes that confer resistance to bleomycin, gentamycin, 
glyphosate, hygromycin, kanamycin, methotrexate, phleo- 
mycin, phosphinotricin, spectinomycin, streptomycin, sul- 
fonamide and sulfonylureas. Maliga et al., Methods in Plant 
Moleculav Biology, Cold Spring Harbor Laboratory Press, 
1995, p. 39. 
[0077] In addition, vectors can also contain marker 
sequences. Suitable markers include, but are not limited to, 
alkaline phosphatase (AP), myc, hemagglutinin (HA), 
0-glucuronidase (GUS), luciferase, and green fluorescent 
protein (GFP). 
[0078] A further embodiment of the present invention 
relates to transformed host cells containing constructs of the 
present invention. The host cell can be a higher eukaryotic 
cell, such as a plant or animal cell, or a lower eukaryotic cell 
such as a yeast cell. Introduction of the construct into the 
host cell can be accomplished by a variety of methods 
including calcium phosphate transfection, DEAE-dextran 
mediated transfection, Polybrene, protoplast fusion, lipo- 
somes, direct microinjection into the nuclei, scrape loading, 
and electroporation. In plants, a variety of different methods 
can be employed to introduce transformation1expression 
vectors into plant protoplasts, cells, callus tissue, leaf discs, 
meristems, etc., to generate transgenic plants. These meth- 
ods include, for example, Agrobacterium-mediated transfor- 
mation, particle gun delivery, microinjection, electropora- 
tion, polyethylene glycol-mediated protoplast 
transformation, liposome-mediated transformation, etc. 
(reviewed in Potrykus (1991) Annu. Rev. Plant Physiol. 
PlantMol. Biol. 42: 205). In one embodiment, plant cells are 
transformed using Agrobacterium-mediated transformation 
and a binary vector system in which the vectors were 
introduced into the Agrobacterium by triparental matings 
(see, Maliga et al., Methods in Plant Moleculav Biology, 
Cold Spring Harbor Laboratory Press, 1995, Sec. 4). 
[0079] Transgenic animals can be produced by the injec- 
tion of the aolvnucleotides of the aresent invention into the 
L ,  
pronucleus of a fertilized oocyte, by transplantation of cells, 
preferably undifferentiated cells, into a developing embryo 
to produce a chimeric embryo, transplantation of a nucleus 
from a recombinant cell into an enucleated embryo or 
activated oocyst, or by any other method capable of pro- 
ducing a transgenic animal. Methods for the production of 
transgenic animals can be found in a number of references 
including, for example, U.S. Pat. No. 4,873,191; Rudolph 
(1999) Trends Biotechnol., 17:367-374; Dalrymple et al. 
(1998) Biotechnol. Genet. Eng. Rev., 15:33-49; Colman 
(1998) Biochem. Soc. Symp., 63:141-147; Wilmut et al., 
(1997) Natuve 385:810-813; Wilmut et al. (1998) Repvod. 
Fevtil. Dev., 10:639-643; Perry et al. (1993) Tvamgenic Res., 
2:125-133; Hogan et al., Manipulating the Mouse Embryo, 
2nd ed., Cold Spring Harbor Laboratory Press, 1994; and 
references cited therein. Of course, gametes, seeds, 
embryos, progeny and hybrids of plants or animals contain- 
ing constructs of the present invention produced by tradi- 
tional breeding methods are also included within the scope 
of the present invention. 
[0080] In general, transgenic plants can be produced by 
transforming plant cells with a DNA construct as described 
above via any of the foregoing methods; selecting plant cells 
that have been transformed on a selective medium; regen- 
erating plant cells that have been transformed to produce 
differentiated plants; and selecting a transformed plant that 
expresses the construct at a level sufficient to result in gene 
suppression. 
[0081] Specific methods for transforming a wide variety of 
dicots and obtaining transgenic plants are well documented 
in the literature (Gasser and Fraley (1989) Science 244: 
1293; Fisk and Dandekar (1993) Scientia Hovticultuvae 55: 
5; Christou (1994) Agro Food Industry Hi Tech, p. 17; and 
the references cited therein). 
[0082] Examples of successful transformation and plant 
regeneration in monocots are as follows: asparagus (Aspava- 
gus officinalis; Bytebier et al. (1987) Pvoc. Natl. Acad. Sci. 
USA 84: 5345); barley (Hovdeum vulgavae; Wan and 
Lemaux (1994) Plant Physiol. 104: 37); maize (Zea mays; 
Rhodes et al. (1988) Science 240: 204; Gordon-Kamm et al. 
(1990) Plant Cell 2: 603; Fromm et al. (1990) BioITechnol- 
ogy 8: 833; Koziel et al. (1993) BioITechnology 11: 194); 
oats (Avena sativa; Somers et al. (1992) BioITechnology 10: 
1589); orchardgrass (Dactylis glomevata; Horn et al. (1988) 
Plant Cell Rep. 7: 469); rice (Ovyza sativa, including indica 
and japonica varieties; Toriyama et al. (1988) BioITechnol- 
ogy 6: 10; Zhang et al. (1988) Plant Cell Rep. 7: 379; Luo 
and Wu (1988) Plant Mol. Biol. Rep. 6: 165; Zhang and Wu 
(1988) Theor: Appl. Genet. 76: 835; Christou et al. (1991) 
BioITechnology 9: 957); rye (Secale ceveale; De la Pena et 
al. (1987) Natuve 325: 274); sorghum (Sorghum bicolov; 
Cassas et al. (1993) Pvoc. Natl. Acad. Sci. USA 90: 11212); 
sugar cane (Saccharum spp.; Bower and Birch (1992) Plant 
J. 2: 409); tall fescue (Festuca avundinacea; Wang et al. 
(1992) BioITechnology 10: 691); turfgrass (Agvostis palus- 
tvis; Zhong et al. (1993) Plant Cell Rep. 13: 1); and wheat 
(Tviticum aestivum; Vasil et al. (1992) BioiTechnology 10: 
667; Weeks et al. (1993) Plant Physiol. 102: 1077; Becker 
et al. (1994) Plant J. 5: 299). 
[0083] Once the construct of the present invention has 
been introduced into the genome of a cell, the desired sense 
or antisense sequence is expressed by the action of the 
promoter. In the case of inducible or developmentally regu- 
lated promoters, expression will not be continuous but rather 
will depend upon the presence of an inducing agent or 
achievement of a developmental stage. In cases where a 
tissue specific promoter has been used, expression will be 
limited to the particular tissue. 
[0084] Because, in one embodiment, the constructs of the 
present invention lack a normal 3' UTR involved in nuclear 
export of transcription products, the RNA produced is 
retained within the nucleus. In another embodiment, the 
construct includes a self-cleaving ribozyme. The self-cleav- 
ing nature of the ribozyme results in the production of free 
sense or antisense RNA. The inability of the transcripts to be 
exported from the nucleus, results in relatively high con- 
centrations of the transcripts within the nucleus. As anti- 
sense RNA transcripts accumulate in the nucleus, they 
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presumably hybridize to any complementary sense RNA 
transcripts. Without being bound by theory, it is believed that 
due to the high concentration of antisense transcripts within 
the nucleus, it is more likely that senselantisense hybrids 
will form than in the cytoplasm where antisense transcripts 
are present at a lower concentration. It is also believed that 
the formation of the hybrids results in an inability of the 
sense RNA (mRNA) to be translated into the encoded 
protein, but instead the hybrid RNA molecule is eventually 
degraded within the nucleus. By preventing translation of 
the mRNA into the encoded protein, the constructs of the 
present invention result in the effective suppression of the 
targeted gene or sequence. Furthermore, the presence of 
senselantisense hybrids in the nucleus will presumably trig- 
ger a sequence-specific RNA degradation pathway, which 
will further reduce the number of transcripts from the target 
gene and increase the efficacy of gene down-regulation. 
[0085] The mechanism by which localization of sense 
transcripts within the nucleus results in suppression of gene 
expression is unknown. Without being bound by theory, the 
mechanism may be similar to that observed with co-sup- 
pression. The present invention, however, differs signifi- 
cantly from traditional co-suppression where co-suppression 
is thought to result from interactions within the cytoplasm, 
while the present invention relies upon the prevention of 
nucleus to cytoplasm transport of RNA transcripts. 
[0086] Once the constructs encompassed by the present 
invention have been successfully introduced into the 
genome of a plant, the plant can be replicated using tradi- 
tional breeding techniques. For example, plants transformed 
with the sense and/or antisense constructs can be "selfed" to 
produce homozygous plants. Additionally, plants of the 
present invention can be crossed to form hybrids containing 
the sense and/or antisense constructs which can then be 
selfed to form a homogeneous population. Thus, the present 
invention encompasses not only plants containing the sense 
and/or antisense constructs of the present invention, but also 
seeds, hybrids and uniform populations produced from such 
plants. 
[0087] Likewise, once the constructs of the present inven- 
tion have been introduced into the genome of an animal, 
such a founder animal can be used to produce offspring by 
any suitable method and the offspring then inbred to produce 
a population homozygous for the construct. 
EXAMPLES 
[0088] The following examples are intended to provide 
illustrations of the application of the present invention. The 
following examples are not intended to completely define or 
otherwise limit the scope of the invention. 
Example 1 
Vectors 
[0089] Plasmid cloning was performed using standard 
procedures (Sambrook et al. Molecular Cloning, 2nd ed., 
Cold Spring Harbor Laboratory Press, 1989). The binary 
vector pPTN102 was assembled by ligating the Hind1111 
EcoRI GUS cassette from pE7131-GUS (Mitsuhara et al. 
(1996) Plant Cell. Physiol. 37:49) into pGPTV-hpt (Becker 
et al. (1992) Plant Molec. Biol. 20:1195). The GUS reporter 
gene was chosen to examine the role of 3'-end modification 
of transcripts in plants. Four constructs were made with the 
GUS reporter gene and a fifth construct without GUS served 
as a negative control (FIG. 1). Plasmid pPTN102 was a 
binary vector that contained GUS driven by the 35s pro- 
moter and ended with a CaMV 35s termination sequence for 
nuclear export. The GUS gene was preceded by the TEV 
leader and the W intron, and the GUS cassette was situated 
between the right border and the hygromycin resistance 
gene. The polyadenylation signal sequence in the plant 
expression vector pRTL2 (Carrington and Freed (1990) J. 
Vlrol. 64:1590) was replaced by a self-cleaving ribozyme 
(RZ) (Liu and Carmichael(l994) Molec. Biotechnol. 2: 107) 
from pBS-RZ-2 (a gift from Gordon Carmichael) to yield 
pPTN106. The GUS open reading frame (ORF) was sub- 
cloned into pPTN106 to yield pPTN108 and pPTN109 
which harbor ribozyme-terminated antisense GUS and sense 
GUS, respectively. The vector pPTN107 is a derivative of 
pRTL2 containing the antisense GUS cassette terminated by 
a polyadenylation signal. The control and GUS cassettes 
from pPTN106, pPTN107, pPTN108 and pPTN109 were 
subcloned as Hind111 fragments into pPZP112 (Hajduk- 
iewicz et al. (1994) Plant Mol. Biol. 25:989) to produce the 
binary vectors pPTN110, pPTN111, pPTN112 and 
pPTN113. Plasmid pPTNlllwas the same as pPTN102 
except GUS was in the antisense orientation. Plasmid 
pPTN112 possessed GUS in the antisense orientation, driven 
by the CaMV 35s promoter and terminated with a cis-acting 
ribozyme to promote generation of a free 3' end and to 
promote nuclear retention, instead of the CaMV 35s termi- 
nation sequence. For pPTN113, GUS was in the sense 
orientation and terminated with a ribozyme. Plasmid 
pPTNllO was a negative control which possessed a TEV 
leader driven by the 35s  promoter and terminated with the 
cis-cleaving ribozyme. Plasmids pPTN110, pPTN111, 
pPTN112 and pPTN113 each had the GUS cassette situated 
between the right border and the kanamycin resistance gene 
instead of the hygromycin resistance gene used for 
pPTN102. At least 3 individual transgenic tobaccos were 
isolated harboring each construct. 
[0090] The embryo-specific, FAD2-1 gene from soybean 
was chosen to determine if the nuclear-localization strategy 
could be employed for endogenous gene down-regulation. 
Four binary constructs containing FAD2-1 were made (FIG. 
2). The FAD2-1 ORF was isolated via PCR from genomic 
DNA (soybean genotype A3237). PCR primers were 
designed to published sequence (Heppard et al. (1996) Plant 
Physiol. 110:311). The primers were Fad2-5 (5'-ttttttctagaac- 
taggcatgggtctagc-3'; SEQ ID NO: 1) and Fad2-3 (5'-tttttg- 
gatccccatcaatacttgttc-3'; SEQ ID NO: 2) with an XbaI site on 
the 5' primer and a BamHI site on the 3' primer. PCR 
reactions included 200 ng of total genomic soybean DNA as 
template, l x  PCR buffer (20 mM Tris-HC1, pH=8.4,50 mM 
KCl), 0.2 mM of each dNTP, 1.5 mM MgCl,, 10 ng of each 
primer and 1 ml of Taq polymerase (Gibco Life Technolo- 
gies Cat. # 18038-042). PCR conditions were: 1 cycle for 5 
minutes at 94' C.; 2 cycles for 1 minute at 94' C., 1 minute 
at 45" C., 2 minutes at 72' C.; 35 cycles for 1 minute at 94' 
C., 1 minute at 55' C., 2 minutes at 72' C.; and a 4" C. 
holding temperature. The PCR product was digested with 
BamHI and XbaI and subcloned into pBluescript KS+ to 
yield pPTN156 and then sequenced. Four expression cas- 
settes were assembled with the FAD2-1 ORF. All expression 
cassettes were under the control of the common bean, 
embryo-specific b-phaseolin promoter (PhP). FAD2-1 was 
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subcloned downstream of the promoter in either sense or 
antisense orientation. The antisense cassettes ended with a 3' 
termination signal or a self-cleaving ribozyme. The respec- 
tive cassettes were cloned into a binary vector which carried 
a bar cassette under the control of the CaMV 35s promoter. 
The resultant vectors, pPTN166, pPTN167, pPTN170 and 
pPTN326, harbored the FAD2-1 cassettes in the following 
orientations: PhP-antisense FAD2-1-RZ, PhP-sense FAD2- 
1-T35S, PhP-antisense FAD2-1-T35S and PhP-sense FAD2- 
1-RZ, respectively. Plasmid pPTN166 contained FAD2-1 in 
antisense orientation driven by the embryo-specific, Phaseo- 
lin promoter and terminated with a ribozyme for nuclear 
localization. Plasmid pPTN167 was a normal co-suppres- 
sion construct. It contained FAD2-1 in sense orientation 
driven by the Phaseolin promoter and ended with the CaMV 
35s terminator for nuclear export. Plasmid pPTN170 was a 
normal antisense construct. It was the same as pPTN167 
except the FAD2-1 gene was in antisense orientation. Plas- 
mid pPTN326 was the same as pPTN166 except FAD2-1 
was in sense orientation. Each of these constructs possessed 
a bar cassette for glufosinate selection. 
[0091] The embryo-specific FatB and FAD2-1 genes were 
employed to show that the nuclear-localized strategy could 
be used to down-regulate multiple genes with a single 
promoter. Two binary constructs, pPTN300 and pPTN303, 
were made containing FatB and FAD2-1, both in sense 
orientation and both driven simultaneously by the embryo- 
specific, b-conglycinin promoter (FIG. 3). 
[0092] The soybean FatB gene was kindly provided by 
Tony Kinney of Dupont as clone pBS56 (A. J. Kinney 
(1997) "Genetic Engineering of oilseeds for Desired Traits" 
in Genetic Engineering vol. 19, pg. 149-166 (Setlow, J. K. 
ed.) Plenum Press, N.Y.). An intermediate vector, FatIRZ 
(PTN309) harboring the b-conglycinin promoter, FatB sense 
ORF and ribozyme was made. The b-conglycinin promoter 
and sense FatB ORF were PCR amplified from pBS56 using 
a 5' primer TB-13, 5'-ATTACGAGCTCAAGCTTGATC- 
CATGCCCTTC-3' (SEQ ID NO: 3), which contains SstI and 
HindIII sites and is complementary to the upstream pro- 
moter sequence, and a 3' primer TB-14, 5'-AATCGGAAT- 
TCAAATC'ITAGGTGCTTTC-3' (SEQ ID NO: 4), which 
contains an EcoRI site and is complementary to the 3'-end of 
the FatB ORF including the stop codon. PCR reactions 
included 100 ng of HindIII-digested pBS56, l x  PCR buffer 
(20 mM Tris-HC1, pH=8.4, 50 mM KCl), 0.2 mM of each 
dNTP, 2 mM MgC1, and 0.1-1 mg of each primer in 100 ml 
volume. PCR reactions were mixed, overlaid with 2 drops of 
mineral oil and brought to 80' C. before adding 0.6 ml of 
Taq polymerase. PCR reactions included 2 cycles at 94' C. 
for 1 minute, 45" C. for 30 seconds, 72" C. for 2 minutes 
followed by 7 cycles at 94' C. for 30 seconds, 55" C. for 30 
seconds, 72" C. for 2.5 minutes and then 1 cycle at 72' C. 
for 5 minutes. The PCR products were digested with SstII 
EcoRI and subcloned into TB-RZ (pPTN304) to yield 
pPTN309. TB-RZ (pPTN304) is a derivative of BS-RZ-2 
(Liu and Carmichael (1994) Molec. Biotechnol. 2:107) 
which was kindly provided by Gordon Carmichael. TB-RZ 
was generated by HindIIIISalI digestion of BS-RZ-2, fol- 
lowed by mung bean nuclease treatment and self-ligation to 
remove relevant restriction sites. DNA sequencing con- 
firmed the removal of restriction sites. 
[0093] Construction of pPTN300 required numerous inter- 
mediate vectors. Soybean FAD2-1 was PCR amplified using 
a 5' primer TB-15, 5'-AATCGCTCGAGACTAG- 
GCATGGGTCTAGC-3' (SEQ ID NO: 5), which contains a 
XhoI site and the ATG start codon of FAD2-1, and a 3' 
primer TB-16, 5'-AAATTGGTACCGAGCTCAAGCT- 
TGAT'ITTGGTTTTAGGAA'ITAG-3'(SEQ ID NO: 6), 
which contains KpnI, SstI and HindIII sites and is comple- 
mentary to downstream sequence of the CaMV35S termi- 
nator. PCR reactions included 908 ng of HindIII-digested 
pPTN167 which harbors the FAD2-1 ORF ended with the 
CaMV35S terminator. PCR reactions contained l x  buffer, 
0.2 mM of each of the 4 dNTPs, 1.5 mM MgC1, and 1 mg 
of each primer. PCR reactions were mixed, overlaid with 2 
drops of mineral oil and brought to 80' C. before adding 0.5 
ml of polymerase (containing 2.5 U of BRL Taq polymerase 
and 0.025 U of Pfu polymerase (Stratagene #600153)). PCR 
reactions included 2 cycles at 94' C. for 30 seconds, 40" C. 
for 30 seconds, 72" C. for 7 minutes followed by 6 cycles at 
94" C. for 30 seconds, 50" C. for 30 seconds, 72" C. for 7 
minutes and then a 72" C. extension for 5 minutes. PCR 
products were digested with XhoIKpnI and subcloned into 
pPTN309 to generate FAT sense/RZ/FAD2-1 senselT35S in 
KS+(pPTN312). The cassette from pPTN312 was digested 
with SstI and subcloned into the binary vector pPTN130 to 
generate pPTN300 (the pertinent sequence arrangement is 
b-conglycinin promoter- FatB sense- RZ- FAD2-1 sense- 
CaMV35S terminator). 
[0094] Construction of pPTN303 also required numerous 
intermediate vectors. FAD2-1 was PCR amplified using 
FAD2-3 and FAD2-5 primers described earlier. PCR reac- 
tions included 100 ng of FAD2-1 template, l x  buffer, 0.2 
mM of each dNTP, 2 mM MgC1, and 0.1-1 mg of each 
primer in 100 ml volume. Reactions were mixed, overlaid 
with 2 drops mineral oil and brought to 80' C. before adding 
0.8 ml of Taq polymerase. PCR reactions included 2 cycles 
at 94" C. for 1 minute, 45" C. for 30 seconds, 72" C. for 2 
minutes followed by 7 cycles at 94' C. for 30 seconds, 55" 
C. for 30 seconds, 72" C. for 2.5 minutes and then a 72" C. 
extension for 5 minutes. Amplification products were cut 
with XbaIBamHI and subcloned into BS-RZ-2 to yield 
FADBS-RZ-2 (pPTN305). Vector pPTN305 was then used 
in another round of PCR to generate a sense FAD2-1/RZ 
sequence with appropriate restriction sites. PCR reactions 
included a 5' primer TB-15 (described above) and a 3' primer 
TB-17, 5'-AAATTGGTACCGAGCTCGACGGTATC- 
GATAAGCTT-3' (SEQ ID NO: 7), which contains KpnI, 
SstI, ClaI and HindIII sites and has identity to the polyclon- 
ing region of pBluescript. PCR reactions included 624 ng of 
pPTN305 digested with SstI/XhoI, l x  buffer, 0.2 mM of 
each dNTP, 1.5 mM MgCl,, 1 mg of each primer in 100 ml 
volume. Reactions were mixed, overlaid with 2 drops of 
mineral oil and brought to 80' C. before adding 0.5 ml of 
polymerase (containing 2.5 U of BRL Taq polymerase and 
0.025 U of Pfu polymerase (Stratagene #600153)). PCR 
reactions included 2 cycles at 94' C. for 30 seconds, 40" C. 
for 30 seconds, 72" C. for 7 minutes followed by 6 cycles at 
94" C. for 30 seconds, 50" C. for 30 seconds, 72" C. for 7 
minutes and then a 72" C. extension for 5 minutes. PCR 
products were digested with XhoIKpnI and sub-cloned into 
pPTN309 to generate FAT senseBZIFAD2-1 sense1RZ in 
KS+ (pPTN313). The cassette from pPTN313 was digested 
with SstI and subcloned into the binary vector pPTN130 to 
generate pPTN303 (the pertinent sequence arrangement is 
b-conglycinin promoter- FatB sense- RZ- FAD2-1 sense- 
RZ). 
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[0095] Plasmids pPTN300 and pPTN303 both contain the 
cis-cleaving ribozyme as a linker between the 2 genes as 
well as a bar cassette for glufosinate selection. The only 
difference between the 2 binaries was that plasmid pPTN300 
was ended with a CaMV 35s terminator and plasmid 
pPTN303 was terminated with a ribozyme. 
Example 2 
Tobacco and Soybean Transformations 
[0096] Binary vectors were mobilized into Agrobacterium 
tumefaciem strain C58C1 (Koncz and Schell (1986) Mol. 
Gen. Genet. 204:383) by triparental matings (Ditta et al. 
(1980) Proc. Natl. Acad. Sci. USA 77:7347). The Agrobac- 
terium transconjugant carrying pPTN102 was selected on 
LB plates supplemented with 50 mg/L rifampicin, 50 mgiL 
gentamicin and 50 mgiL kanamycin. Agrobacterium 
transconjugants carrying pPTN110, pPTN111, pPTN112 
and pPTN113 were selected on LB supplemented with 50 
mg/L rifampicin, 50 mg/L gentamicin and 75 mgiL chloram- 
phenicol. Agrobacterium transconjugants carrying 
pPTN166, pPTN167, pPTN170, pPTN326, pPTN300 and 
pPTN303 were selected on LB supplemented with 50 mgiL 
rifampicin, 50 mgiL gentamicin, 100 mgiL streptomycin and 
100 mg/L spectinomycin. Binary vectors in Agrobacterium 
were confirmed by plasmid preps and restriction digestion 
(Sambrook et al., Molecular Cloning, 2nd ed., Cold Spring 
Harbor Laboratory Press, 1989). 
[0097] Tobacco (cultivar Xanthi) transformations were 
conducted via the leaf disc method described by Horsch et 
al. (1985) Science 227:1229. Transformants were selected 
on 10 mg/L hygromycin (pPTN102) or 150 mgbkanamycin 
(pPTN110, pPTN111, pPTN112 or pPTN113). Soybean 
transformations were conducted as described by Zhang et al. 
(1999) Plant Cell, Tissue and Organ Culture 56:37) using 
the cotyledonary-node transformation system (Hinchee et al. 
(1988) BioITechnol. 6:915; Clemente et al. (2000) Crop Sci. 
40:797). Transformants were selected on 5 mgiL glufosinate 
during shoot initiation and 3 mg/L during shoot elongation 
steps. 
Example 3 
RNA Isolation and Northern Blottinq 
[0098] Comparison of the CaMV 35s terminator and the 
cis-acting ribozyme with respect to sub-cellular transcript 
localization was made using transgenic tobacco harboring 
GUS constructs (FIG. 1). Evaluation of the foreign GUS 
gene alleviated potential problems with gene silencing or 
endogenous gene expression. To ascertain the sub-cellular 
location of transcripts produced by the different clones, total 
RNA and nuclei RNA were isolated from approximately 2 
week old seedlings. A comparison of total RNA to nuclei 
RNAwas made because RNAisolation from these compart- 
ments was much simpler and efficient compared to isolation 
of cytoplasmic RNA from plants. Furthermore, the data 
derived from these experiments was much simpler to stan- 
dardize and interpret compared to isolation of cytoplasmic 
RNA. This is because it is difficult to assess the amount of 
RNA that is present from broken nuclei when using cyto- 
plasmic RNA samples and isolation of cytoplasmic RNA 
requires inconsistent and lengthy protocols. 
[0099] Transgenic GUS tobacco seeds were sterilized by 
suspending approximately 200-500 seeds in 1 ml of 50% 
Clorox@, 0.02% Triton X-100 with constant agitation for 5 
minutes at room temperature (RT). Samples were then spun 
at 735x n for 5 seconds and the Clorox@ solution removed a 
with a pipette. Seeds were then resuspended in 1 ml of sterile 
deionized distilled water (ddH20) with constant agitation for 
1 minute at room temperature followed by a brief 735x g 
spin and removal of the water. Seeds were washed with 
ddH20 a total of 4 times. Each sample was then suspended 
in 1 ml of ddH20 and transferred to a tube with 9 ml of 0.2% 
Type A agar amended with 100 mg cefotaxime/L. This was 
overlaid onto 150 mmxl5 mm petri plates containing selec- 
tion medium: 0 . 5 ~  Murashige-Skoog salts and l x  Fe-ethyl- 
ene diamine tetraacetic acid (EDTA) (Murashige and Skoog 
(1962) Physiol. Plant 15:473), 1% sucrose, pH=5.7, 0.7% 
Type A agar, l x  Gamborg B5 vitamins (Gamborg et al. 
(1968) Exp. Cell Res. 50:151) amended with 15 mg hygro- 
mycin1L andlor 100 mg kanamycin1L. Plates were wrapped 
with Parafilm@ and incubated in a 24" C. growth chamber 
with a 16 hour light18 hour dark photoperiod. 
[0100] After a 2-3 week selection period, numerous whole 
seedlings were harvested and weighed. Seedlings were then 
subjected to RNA isolation. For intact RNA isolation, 100 
mg of seedlings was processed with 0.75 ml Trizol LS (Life 
Technologies, Inc., GibcoBRL, Rockville, MD) plus 0.1 ml 
ddH-0 accordinn to the manufacturer's instructions. Two 
'. u 
exceptions to the manufacturer's protocol included an addi- 
tional chloroform extraction prior to isopropanol precipita- 
tion and RNA suspension in 100% formamide. 
[0101] For total RNA and nuclei RNA isolation, seedlings 
were ground in an ice-cold mortar with a glycerol extraction 
buffer (10 mM HEPES, pH=8.0, 40% glycerol, 5 mM 
MgCl,, 0.1 mM EDTA) at a ratio of 300 mg tissue per 1 ml 
of ice-cold extraction buffer. For total RNA isolation, 0.25 
ml of the homogenate was mixed with 0.75 ml of Trizol LS. 
For nuclear RNA isolation, the remaining homogenate was 
filtered through 1 layer of 33 mM nylon mesh (pre-washed 
with ddH20 and autoclaved) into a centrifuge tube on ice. 
The filtrate was spun in Eppendorf tubes at 1 , 3 1 0 ~  g for 
30-60 seconds. The supernatant was removed with a pipette. 
The crude nuclei/organelle pellet was then resuspended in 1 
ml of cold extraction buffer by gentle inversion. Samples 
were next spun at 1 , 3 1 0 ~  g for 30-60 seconds and the 
supernatant was removed with a pipette. At this point, the 
crude nuclei pellet was free from cell walls, cytoplasmic 
components, and broken organelles. The resulting pellet(s) 
was suspended in 0.25 ml of cold extraction buffer giving a 
total volume of 0.3-0.35 ml. The crude nuclei suspension 
was then mixed with 1.1 ml of Trizol LS. RNA extractions 
were as above. 
[0102] For Northern analysis 10 mg of RNA or 3 ml of 
RNA marker (Life Technologies, Inc., GibcoBRL, Rock- 
ville, Md., cat # 15260-016) was combined with formamide, 
1 ml of ethidium bromide (10 mg per ml), 0.45 ml formal- 
dehyde, and 2 ml of lox  MESA buffer (0.4M MOPS, 
pH=7.0, 0.1M NaAc, 10 mM EDTA) in 18 ml volume. 
Samples were incubated at 75' C. for 5 minutes and then set 
on ice. Next, 2 ml of lox stop dye (0.05% bromophenol 
blue, 40% sucrose, 0.1M EDTA, 0.5% sodium dodecyl 
sulfate (SDS)) was added. Samples were loaded onto a 1% 
agarose, l x  buffer ( l x  MESA buffer, 0.3M formaldehyde) 
gel and ran in l x  buffer at 1.5-2.5 Vlcm for up to 6 hours. 
Gels were washed by immersing 2 times in ddH20 and then 
2 times in 2x SSC (Sambrook et al. Molecular Cloning, 2nd 
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ed., Cold Spring Harbor Laboratory Press, 1989). Washes 
were at room temperature with gentle agitation for 10 
minutes each. RNA was transferred to positive nylon mem- 
branes (BioRad Laboratories, Hercules, Calif.) using 20x 
SSC for 12-18 hours and subsequently fixed via UV irra- 
diation. Filters were hybridized in 25 ml of 7% SDS, 0.5M 
Na2HP0,, pH=7.2,1 mM EDTA, 1% bovine serum albumin 
(BSA) amended with 10-15 ng of denatured probe. Probes 
were labeled with [a-32P]dCTP using the random priming kit 
from Stratagene (La Jolla, Calif.). Hybridizations were incu- 
bated 14-20 hours at 65' C. Filters were washed under high 
stringency including 2 washes of 0 . 2 ~  SSC, 0.1% SDS at 
65" C. for 10 minutes each. Filters were exposed to film with 
intensifying screens at -80' C. 
[0103] The results are shown in FIG. 4. Nuclei staining in 
FIG. 4 shows that good nuclei were isolated. The large red 
bodies are intact nuclei. The smaller, yellow-green bodies 
are chloroplasts. These crude nuclei (organelle) fractions 
were filtered and washed free of cytoplasmic components. 
This contrasts with total nuclei RNA preps which contain 
nuclei RNA, organelle RNA, and all cytoplasmic RNA 
regardless of the RNA location within or among the plant 
cells. Thus nuclei RNA samples have a much higher con- 
centration of nuclei RNA than total RNA samples. 
[0104] A TEV leader-GUS probe was used for Northern 
analysis in FIG. 5. GUS expression for pPTN113 was very 
low and this was observed for numerous individuals har- 
boring pPTN113. The Northerns showed much higher levels 
of total RNA than nuclear RNA for clones pPTN102 and 
pPTN111. Subtraction of nuclear RNA from total RNA 
implied that the majority of transcripts generated by these 2 
clones resided outside of the nucleus. The opposite hybrid- 
ization pattern was seen for clones pPTN110, pPTN112 and 
pPTN113. These ribozyme-terminated constructs yielded 
transcripts which appeared to accumulate exclusively in the 
nucleus. The smaller molecular weight for the signal seen 
for pPTNllO was exclusive to pPTNllO since it is the only 
construct that expressed a TEV leader but no FAD2-1 ORF. 
Example 4 
In Situ Hybridization 
[0105] All procedures were carried out at RT unless indi- 
cated otherwise. Root tips, taken from 2 week-old seedlings 
grown on agar selection medium as described above, were 
fixed in 4% paraformaldehyde in PBS (Sambrook et al., 
Molecular Cloning, 2nd ed., Cold Spring Harbor Laboratory 
Press, 1989) for 2 hours. Roots were washed twice in PBS 
for 10 minutes each, once in PBS amended with 1 mgiml 
sodium borohydride for 10 minutes, and once in PBS plus 
0.2% Triton X-100 for 15 minutes. Samples were incubated 
in PBS containing 30% sucrose overnight at 4' C. Frozen 
sections (8 mM in thickness) were collected on po1y-L- 
lysine coated slides, air dried and stored at -20' C. overnight 
before use. Slides containing sample sections were treated 
with 0.2 N HC1 for 5 minutes, proteinase-K (5 uglml in TE 
(10 mM Tris, 1 mM EDTA, pH=8.0)) for 10-15 minutes at 
37" C., and 0.25% acetic anhydride plus 0.1M triethanola- 
mine for 10 minutes. Samples were incubated in prehybrid- 
ization buffer (5x SSC, l x  Denhardt's solution, 1% SDS, 50 
mglml denatured salmon sperm DNA, 50% formamide, 20 
mM sodium phosphate, pH=6.6) for 2 hours at 50' C. 
followed by an overnight hybridization at 50' C. in the same 
buffer plus 10% dextran sulfate and GUS probe (1-2 mgiml). 
GUS probes were antisense or sense-specific, DIG-labeled 
RNA probes which were polymerized and then hydrolyzed 
to less than 500 base pairs using the DIG labeling system 
from Roche Molecular Biochemicals Inc. (Indianapolis, 
Ind.). After washing with 2x SSC at 60' C. for 10 minutes 
and 37" C. for 10 minutes, slides were treated with 0.2 
mglml RNAase Ain 2x SSC, followed by a series of washes 
with SSC. The final wash was with 0 . 2 ~  SSC at 37' C. for 
30 minutes. Samples were rinsed once in TTBS (0.05% 
Tween 20, l x  TBS (20 mM Tris, 0.5M NaC1, pH=7.5)) and 
then incubated with TTBS plus 5% BSA (Fraction-V) for 1 
hour. Slides were then incubated in TTBS containing 1% 
BSA and FITC-conjugated sheep anti-DIG antibodies (1:5 
dilution, Roche Molecular Biochemicals, Inc.) for 2 hours. 
After 2 washes with TTBS and 1 wash with TBS (10 minutes 
each), the slides were stained with 10 mglml propidium 
iodide (DNA-staining) for 5 minutes, rinsed in TBS, and 
mounted immediately for image collection. Images were 
collected with a BioRad MRC1024ES confocal laser scan- 
ning microscope using a dual excitation (4881568 nm) and 
dual emission (5201598 nm) program. 
[0106] In situ hybridization using strand-specific GUS 
probes and subcellular microscopy corroborated the North- 
ern results. FIG. 6 shows hybridization results for transgenic 
individuals harboring pPTNll l  or pPTN112 which 
expressed cytoplasm-localized GUS and nuclear-localized 
GUS, respectively. The red channel showed nuclei staining 
and the green channel showed in situ hybridization of 
strand-specific probes. Comparing the green channel of 
pPTNll l  sense and antisense showed a much more intense, 
disperse signal with the sense probe although some back- 
ground was present with the antisense probe. The combined 
channel shows yellowing of nuclei using the sense probe but 
not the antisense probe indicating specific hybridization by 
the sense probe. This was expected since some of the GUS 
RNA should still be in the nuclei for pPTNll l  transgenics 
even though most of the RNA had been exported out of the 
nucleus. Comparing the green channel of pPTN112 sense 
and antisense showed staining of nuclei that was specific 
only for the sense probe. There was some background 
emanating from what appeared to be cell structure. Again, 
the combined channel showed yellowing of nuclei for the 
sense probe indicating specific binding by the sense probe 
but not the antisense probe. Comparison of pPTNll l  and 
pPTN112 showed that the sense probe was disperse in the 
pPTNlllsample and concentrated in the nucleus for 
pPTN112. 
Example 5 
Fatty Acid Analysis 
[0107] Seeds or seed chips for 4 to 8 TI ,  T2 or T3 
generation of transgenic soybeans were used for fatty acid 
analysis. Fatty acid analysis was performed using gas chro- 
matography according to the procedure of Butte et al. 
((1982) Analytical Lett., 15(A10):841-850). 
[0108] Transgenic soybeans were selected with glufosi- 
nate, and the presence of a T-DNA was confirmed by 
Southern analysis (data not shown). Fatty acid analysis was 
performed on up to 8 seed chips from each T1 transgenic 
(Table 1). Ahigh oleic acid phenotype was observed for 3 of 
4 transgenic soybeans harboring nuclear-localized antisense 
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FAD2-1 (pPTN166). Transgenics 1-3, 1-5 and 1-6 yielded 
an average of 63.0+6.2% oleic acid compared to 13.7% for 
wild-type. A high oleic acid phenotype was observed for 2 
of 9 transgenic soybeans harboring cytoplasm-localized 
antisense FAD2-1 (pPTN170). Transgenics 3-1 and 3-2 
yielded an average of 83.0+1.1% oleic acid compared to 
13.7% for wild-type. Two of the eight soybean transformants 
carrying the sense nuclear-localized FAD2-1 (pPTN326) 
displayed an elevated oleic acid phenotype as shown in 
Table 1. Soybean transformants 6-1, and 6-2 possessed oleic 
acid levels of 77.2% and 77.3% respectively. As expected, 
the high oleate acid phenotype came primarily at the 
expense of polyunsaturates (18:2+18:3), although there was 
also a noticeable decrease in saturates (16:0+18:0). There 
were no high oleate transgenics harboring the normal cosup- 
pression construct pPTN167. 
[0109] Transgenic soybeans with dual gene constructs 
were selected with glufosinate and the presence of a T-DNA 
was confirmed by Southern analysis (data not shown). Fatty 
acid analysis was performed on up to 8 seed chips from each 
T1 transgenic (Table 2). A high oleate acid phenotype was 
observed for 6 of 15 transgenic soybeans harboring 
pPTN300. Five of these transgenics 4-3, 4-6, 4-14 and 4-15 
yielded an average of 66.2+11.0% oleic acid compared to 
13.7% for wild-type. The decrease in polyunsaturates 
(18:2+18:3) indicated down-regulation of the FAD2-1 
desaturase. Transgenic 4-2 was the only pPTN300 trans- 
genic with a highly significant decrease in saturated fatty 
acids (16:0+18:0) in addition to a large increase in oleic acid. 
This transgenic had 5.7% saturates compared to 15.8% for 
wild-type which indicated that the FatB thioesterase gene 
had been down-regulated, while the increase in oleic acid 
and decrease in polyunsaturates was the result of down- 
regulated FAD2-1. A high oleate phenotype was observed 
for 5 of 27 transgenic soybeans harboring pPTN303. Four of 
the five pPTN303 transgenics (5-3, 5-5, 5-10 and 5-24) 
yielded an average of 89.2%+1.6% compared to 13.7% for 
wild-type. The great decrease in polyunsaturates and 
increase in oleic acid indicated strong FAD2-1 down-regu- 
lation. Importantly, the saturated fatty acid composition 
(16:0+18:0) of these four pPTN303 transgenics was 
decreased to an average of 5.2%+0.3% compared to 15.8% 
for wild-type indicating FatB thioesterase down-regulation 
in all 3 transnenics. Thus. the ribozvme-terminated 
- 
pPTN303 construct produced a very dramatic phenotype and 
was more effective for down regulating multiple genes at 
one time compared to pPTN300. 
Conclusion 
[0110] In light of the detailed description of the invention 
and the examples presented above, it can be appreciated that 
the several aspects of the invention are achieved. 
[Olll] It is to be understood that the present invention has 
been described in detail by way of illustration and example 
in order to acquaint others skilled in the art with the 
invention, its principles, and its practical application. Par- 
ticular formulations and processes of the present invention 
are not limited to the descriptions of the specific embodi- 
ments presented, but rather the descriptions and examples 
should be viewed in terms of the claims that follow and their 
equivalents. While some of the examples and descriptions 
above include some conclusions about the way the invention 
may function, the inventors do not intend to be bound by 
those conclusions and functions, but put them forth only as 
possible explanations. 
[0112] It is to be further understood that the specific 
embodiments of the present invention as set forth are not 
intended as being exhaustive or limiting of the invention, 
and that many alternatives, modifications, and variations 
will be apparent to those of ordinary skill in the art in light 
of the foregoing examples and detailed description. Accord- 
ingly, this invention is intended to embrace all such alter- 
natives, modifications, and variations that fall within the 
spirit and scope of the following claims. 
TABLE 1 
Fatty Acid Profiles of Transgenic Soybeans 
Harboring Vectors PTN166, PTN167 or PTN170 
No. Event Vector 16:O 18:O 18:l 18:2 18:3 
[0113] 
TABLE 2 
Fatty Acid Profiles of Transgenic Soybeans 
Harboring Vectors PTN300 or PTN303 
No. Event Vector 16:O 18:O 18:l 18:2 18:3 
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TABLE 2-continued TABLE 2-continued 
Fatty Acid Profiles of Transgenic Soybeans 
Harboring Vectors PTN300 or PTN303 
No. Event Vector 16:O 18:O 18:l 18:2 18:3 
Fatty Acid Profiles of Transgenic Soybeans 
Harboring Vectors PTN300 or PTN303 
No. Event Vector 16:O 18:O 18:l 18:2 18:3 
SEQUENCE L I S T I N G  
< 1 6 0 >  NUMBER O F  S E Q  I D  NOS: 7  
< 2 1 0 >  S E Q  I D  NO 1 
< 2 1 1 >  LENGTH: 2 9  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<2 2  0  > FEATURE : 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 2 9 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: I 
t t t t t t c t a g  a a c t a g g c a t  g g g t c t a g c  
< 2 1 0 >  S E Q  I D  NO 2  
< 2 1 1 >  LENGTH: 2 7  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<2 2  0  > FEATURE : 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 2 7 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 2  
t t t t t g g a t c  cccatcaata c t t g t t c  
< 2 1 0 >  S E Q  I D  NO 3  
< 2 1 1 >  LENGTH: 3 1  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<2 2  0  > FEATURE : 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 3 1 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 3  
a t t a c g a g c t  c a a g c t t g a t  c c a t g c c c t t  c 
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< 2 1 0 >  S E Q  I D  NO 4  
< 2 1 1 >  LENGTH: 2 8  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
< 2 2 0 >  FEATURE: 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 2 8 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 4  
a a t c g g a a t t  c a a a t c t t a g  g t g c t t t c  
< 2 1 0 >  S E Q  I D  NO 5  
< 2 1 1 >  LENGTH: 2 9  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
< 2 2 0 >  FEATURE: 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 2 9 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 5  
a a t c g c t c g a  g a c t a g g c a t  g g g t c t a g c  
< 2 1 0 >  S E Q  I D  NO 6 
< 2 1 1 >  LENGTH: 4 4  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
< 2 2 0 >  FEATURE: 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 4 4 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 6 
a a a t t g g t a c  c g a g c t c a a g  c t t g a t t t t g  g t t t t a g g a a  t t a g  
< 2 1 0 >  S E Q  I D  NO 7 
< 2 1 1 >  LENGTH: 3 5  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
< 2 2 0 >  FEATURE: 
< 2 2 1 >  NAME/KEY: m i s c - f e a t u r e  
< 2 2 2 >  LOCATION: ( 1 ) . . ( 3 5 )  
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 7 
a a a t t g g t a c  c g a g c t c g a c  g g t a t c g a t a  a g c t t  
What is claimed is: 
1. A method for suppressing gene expression in a eukary- 
otic cell comprising, transforming said cell with a recom- 
binant construct comprising, a promoter functional in said 
cell operatively linked to a sense nucleotide sequence of a 
gene to be suppressed, wherein nucleus-to-cytoplasm trans- 
port of transcription products of said construct is inhibited. 
2. The method of claim 1, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a normal 
3' UTR. 
3. The method of claim 1, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a 3' 
terminal sequence. 
4. The method of claim 1, wherein said construct further 
comprises at least one self cleaving ribozyme. 
5. The method of claim 1, wherein said promoter is 
selected from the group consisting of a constitutive pro- 
moter, an inducible promoter, a tissue specific promoter, and 
a developmentally regulated promoter. 
6. The method of claim 1, wherein said construct further 
comprises at least one additional sense nucleotide sequence 
of at least one additional gene operatively linked to said 
promoter. 
7. A method for suppressing gene expression in a eukary- 
otic cell comprising, transforming said cell with a recom- 
binant construct comprising, a promoter functional in said 
cell operatively linked to a plurality of antisense nucleotide 
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sequences of a gene or genes to be suppressed, wherein 
nucleus-to-cytoplasm transport of transcription products of 
said construct is inhibited. 
8. The method of claim 7, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a normal 
3' UTR. 
9. The method of claim 7, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a 3' 
terminal sequence. 
10. The method of claim 7, wherein said construct further 
comprises at least one self cleaving ribozyme. 
11. The method of claim 7, wherein said promoter is 
selected from the group consisting of a constitutive pro- 
moter, an inducible promoter, a tissue specific promoter, and 
a developmentally regulated promoter. 
12. A method for suppressing expression of a gene in a 
plant cell, comprising transforming said plant cell with a 
recombinant construct comprising, a promoter functional in 
said plant cell, and an antisense nucleotide sequence for the 
gene to be suppressed, wherein nucleus-to-cytoplasm trans- 
port of transcription products of said construct is inhibited. 
13. The method of claim 12, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a normal 
3' UTR. 
14. The method of claim 12, wherein said construct 
further comprises at least one self cleaving ribozyme. 
15. The method of claim 12, wherein said promoter is 
selected from the group consisting of a constitutive pro- 
moter, an inducible promoter, a tissue specific promoter, and 
a developmentally regulated promoter. 
16. A recombinant vector comprising, a promoter func- 
tional in a eukaryotic cell operatively linked to a nucleotide 
sequence selected from the group consisting of: 
a) at least one sense nucleotide sequence of at least one 
gene to be suppressed, 
b) a plurality of antisense nucleotide sequences of at least 
one gene to be suppressed, and 
c) at least one antisense nucleotide sequence for at least 
one gene to be suppressed; 
wherein nucleus-to-cytoplasm transport of transcription 
products of said at least one nucleotide sequence is 
inhibited. 
17. The recombinant vector of claim 16, wherein said 
inhibition of nucleus-to-cytoplasm transport is due to a lack 
of a normal 3' UTR. 
18. The recombinant vector of claim 16, wherein said 
construct further comprises at least one self cleaving 
ribozyme. 
19. The recombinant vector of claim 16, wherein said 
promoter is selected from the group consisting of a consti- 
tutive promoter, an inducible promoter, a tissue specific 
promoter, and a developmentally regulated promoter. 
20. A host cell comprising the recombinant vector of 
claim 16. 
21. A eukaryotic cell whose genome includes a recombi- 
nant construct comprising, a promoter functional in said 
eukaryotic cell operatively linked to at least one sense 
nucleotide sequence of at least one gene to be suppressed, 
wherein nucleus-to-cytoplasm transport of transcription 
products of said construct is inhibited. 
22. The eukaryotic cell of claim 21, wherein said inhibi- 
tion of nucleus-to-cytoplasm transport is due to a lack of a 
3' terminal sequence. 
23. The eukaryotic cell of claim 21, wherein said inhibi- 
tion of nucleus-to-cytoplasm transport is due to a lack of a 
normal 3' UTR. 
24. The eukaryotic cell of claim 21, wherein said con- 
struct further comprises at least one self cleaving ribozyme. 
25. The eukaryotic cell of claim 21, wherein said pro- 
moter is selected from the group consisting of a constitutive 
promoter, an inducible promoter, a tissue specific promoter, 
and a developmentally regulated promoter. 
26. A plant comprising at least one cell of claim 21. 
27. A eukaryotic cell whose genome includes a recombi- 
nant construct comprising, a promoter functional in said 
eukaryotic cell operatively linked to a plurality of antisense 
nucleotide sequences of at least one gene to be suppressed, 
wherein nucleus-to-cytoplasm transport of transcription 
products of said construct is inhibited. 
28. The eukaryotic cell of claim 27, wherein said inhibi- 
tion of nucleus-to-cytoplasm transport is due to a lack of a 
normal 3' UTR. 
29. The eukaryotic cell of claim 27, wherein said inhibi- 
tion of nucleus-to-cytoplasm transport is due to a lack of a 
3' terminal sequence. 
30. The eukaryotic cell of claim 27, wherein said con- 
struct further comprises at least one self cleaving ribozyme. 
31. The eukaryotic cell of claim 27, wherein said pro- 
moter is selected from the group consisting of a constitutive 
promoter, an inducible promoter, a tissue specific promoter, 
and a developmentally regulated promoter. 
32. A plant comprising at least one cell of claim 27. 
33.  plant cell-whose genome includes a recombinant 
construct comprising, a promoter functional in said plant 
cell operatively linked to at least one antisense sequence for 
at least one gene to be suppressed; wherein nucleus-to- 
cytoplasm transport of transcription products of said con- 
struct is inhibited. 
34. The plant cell of claim 33, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a normal 
3' UTR. 
35. The plant cell of claim 33, wherein said inhibition of 
nucleus-to-cytoplasm transport is due to a lack of a 3' 
terminal sequence. 
36. The plant cell of claim 33, wherein said construct 
further comprises at least one self cleaving ribozyme. 
37. The plant cell of claim 33, wherein said promoter is 
selected from the group consisting of a constitutive pro- 
moter, an inducible promoter, a tissue specific promoter, and 
a developmentally regulated promoter. 
38. A plant comprising at least one cell of claim 33. 
39. A seed from the plant of claim 38. 
40. The progeny of the plant of claim 38. 
